Yves Leestemaker
Impact in
-
- Alzheimer's disease research and treatments
Papers in
-
- Ubiquitin and proteasome pathways 6
- Protein Degradation and Inhibitors 4
- Histone Deacetylase Inhibitors Research 2
- Glycosylation and Glycoproteins Research 1
- Oncology 2
- Peptidase Inhibition and Analysis 2
- Co-authors
- Huib Ovaa (7 shared papers)Cheryl Herrera (1 shared paper)Rik van der Kant (1 shared paper)Steven L. Wagner (1 shared paper)J. Bernd Helms (1 shared paper)Martin Giera (1 shared paper)Jos F. Brouwers (1 shared paper)Lawrence S.B. Goldstein (1 shared paper)
- Journals
- Molecular Pharmaceutics (1 paper)Cell stem cell (1 paper)The Journal of Immunology (1 paper)Cell chemical biology (1 paper)Drug Discovery Today Technologies (1 paper)
- Partner nations
- NetherlandsUnited StatesGermany
In The Last Decade
Yves Leestemaker
7 papers receiving 516 citations
Peers
Comparison fields: 5 of 63
- Biological Psychiatry 13
- Physiology 124
- Molecular Biology 340
- Neurology 38
- Cell Biology 75
Countries citing papers authored by Yves Leestemaker
This map shows the geographic impact of Yves Leestemaker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yves Leestemaker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yves Leestemaker more than expected).
Fields of papers citing papers by Yves Leestemaker
This network shows the impact of papers produced by Yves Leestemaker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yves Leestemaker. The network helps show where Yves Leestemaker may publish in the future.
Co-authors
The 25 scholars most cited alongside Yves Leestemaker, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2019 | 242 | |
| 2 | 2017 | 119 | |
| 3 | 2017 | 73 | |
| 4 | 2012 | 40 | |
| 5 | 2019 | 32 | |
| 6 | 2017 | 13 | |
| 7 | 2016 | 4 |
About Yves Leestemaker
Yves Leestemaker is a scholar working on Molecular Biology, Oncology, Surgery, Biological Psychiatry and Hematology, having authored 7 papers that have together received 523 indexed citations. Recurring topics across this work include Ubiquitin and proteasome pathways (6 papers), Protein Degradation and Inhibitors (4 papers), Histone Deacetylase Inhibitors Research (2 papers), Peptidase Inhibition and Analysis (2 papers), Alzheimer's disease research and treatments (1 paper), Tryptophan and brain disorders (1 paper), Cholesterol and Lipid Metabolism (1 paper) and Glycosylation and Glycoproteins Research (1 paper). The work is most often cited by research in Biological Psychiatry (13 citations), Physiology (124 citations), Molecular Biology (340 citations), Neurology (38 citations) and Cell Biology (75 citations). Yves Leestemaker has collaborated with scholars based in Netherlands, United States and Germany. Frequent co-authors include Huib Ovaa, Cheryl Herrera, Rik van der Kant, Steven L. Wagner, J. Bernd Helms, Martin Giera, Jos F. Brouwers, Lawrence S.B. Goldstein, Evelyne Steenvoorden and Kevin D. Rynearson. Their work appears in journals such as Molecular Pharmaceutics, Cell stem cell, The Journal of Immunology, Cell chemical biology and Drug Discovery Today Technologies.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.